5G1: Phase I trial of 5G1.1-SC.

Alexion Pharmaceuticals Inc. (ALXN), New Haven, Conn. Product: 5G1.1-SC, C5 inhibitor of the complement cascade Indication: Prevent inflammation during cardiopulmonary bypass Status: ALXN began a Pha...